Biomerieux SA operates in the Diagnostic substances sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Biomerieux SA with three other
pharmaceutical manufacturers in Europe:
Stada Arzneimittel AG
sales of 2.31 billion Euro [US$2.83 billion]
of which 59%
H. Lundbeck A/S
(17.23 billion Danish Kroner [US$2.82 billion]
of which 18%
was Onfi), and
(2.01 billion Euro [US$2.46 billion]
of which 79%
was Specialty Care).
Biomerieux SA reported sales of 2.29 billion Euro (US$2.79 billion)
December of 2017.
increase of 8.8%
versus 2016, when the company's sales were 2.10 billion Euro.
Sales at Biomerieux SA have increased during each of the previous five years
(and since 2012, sales have increased a total of 46%).
Sales of Diagnostic Clinical Equipment saw an increase
10.3% in 2017, from
1.68 billion Euro to 1.85 billion Euro.
Not all segments of Biomerieux SA experienced an increase in sales in 2017:
sales of Co-Development Program fell 51.6% to 3.10 million Euro.
(However, this segment's sales were only a very small portion of the company's overall sales).
Biomerieux SA also experienced decreases in sales in
Biofire Defense (down 44.0% to 19.70 million Euro)
Applied Maths (down 10.5% to 3.40 million Euro)